City of Hope takes a Commercial Product License to use ProBioGen’s AGE1.CR® Vaccine Manufacturing Platform
Berlin, Germany and Duarte, USA, June 9, 2021: ProBioGen AG has announced a commercial product license agreement with City of Hope, a world-renowned independent research and..
ProBioGen and Minapharm Pharmaceuticals incorporate MiGenTra GmbH – A Healthcare Transforming Medicines Company
Berlin, Germany and Cairo, Egypt, May 27, 2021: ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin..
ProBioGen und Minapharm Pharmaceuticals gründen die MiGenTra GmbH mit dem Ziel, das Gesundheitswesen zu verändern
Berlin, Deutschland und Kairo, Ägypten, 27. Mai 2021: ProBioGen und Minapharm Pharmaceuticals geben die Gründung von ProBioGens Tochtergesellschaft "MiGenTra" bekannt. Die neue..
Asher Biotherapeutics contracts ProBioGen to develop and manufacture their Lead Candidate
Berlin, Germany, April 26, 2021: ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development,..
Nouscom activates Commercial Product License for ProBioGen’s proprietary Vaccine Production Cell Line AGE1.CR.pIX®
Berlin, Germany, April 15, 2021: ProBioGen announced today that Nouscom has activated a commercial product license to ProBioGen's innovative, cell-based vaccine platform..
ProBioGen enters into Agreement with Nobelpharma for Manufacturing Process Development of their Vaccine Project
Berlin, March 24, 2021: ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project. Earlier work confirmed already..
ProBioGen licenses GlymaxX® Technology to Sanofi
Enhancement of Target Cell Killing for Innovative Therapies Berlin, March 17, 2021: ProBioGen AG has signed a commercial multi-product license agreement with Sanofi. Under such..
ProBioGen Successfully Completes CMC Development Milestones for Marea’s Promising Acromegaly Therapeutic
Mar 6, 2025
ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded Portfolio
Feb 4, 2025
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development
Nov 5, 2024
ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development
May 29, 2024
ProBioGen and DIOSynVax Partner to Manufacture Groundbreaking Multivalent Vaccine for Hemorrhagic Fever
Mar 27, 2024
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Mar 13, 2024
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
Sep 26, 2023
